These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 3923922)

  • 1. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.
    Sutherland R; Boon RJ; Griffin KE; Masters PJ; Slocombe B; White AR
    Antimicrob Agents Chemother; 1985 Apr; 27(4):495-8. PubMed ID: 3923922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus.
    Casewell MW; Hill RL
    J Antimicrob Chemother; 1985 May; 15(5):523-31. PubMed ID: 3924877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(3):279-82. PubMed ID: 2507218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent.
    Casewell MW; Hill RL
    J Antimicrob Chemother; 1987 Jan; 19(1):1-5. PubMed ID: 3104272
    [No Abstract]   [Full Text] [Related]  

  • 5. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.
    Fuchs PC; Jones RN; Barry AL
    J Clin Microbiol; 1990 Mar; 28(3):608-9. PubMed ID: 2108997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of teichomycin against isolates of gram-positive bacteria.
    Fietta A; Bersani C; Mangiarotti P; Gialdroni Grassi G
    Chemotherapy; 1983; 29(4):275-82. PubMed ID: 6223793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of norfloxacin (MK-0366).
    King A; Warren C; Shannon K; Phillips I
    Antimicrob Agents Chemother; 1982 Apr; 21(4):604-7. PubMed ID: 6211139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Ward A; Campoli-Richards DM
    Drugs; 1986 Nov; 32(5):425-44. PubMed ID: 3098541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of mupirocin, a new topical agent against Staphylococcus aureus].
    Rosales Rodríguez M
    Enferm Infecc Microbiol Clin; 1990 Nov; 8(9):572-3. PubMed ID: 2129195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of mupirocin transport into sensitive and resistant bacteria.
    Capobianco JO; Doran CC; Goldman RC
    Antimicrob Agents Chemother; 1989 Feb; 33(2):156-63. PubMed ID: 2497702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity of REP8839, a new antibiotic for topical use.
    Critchley IA; Young CL; Stone KC; Ochsner UA; Guiles J; Tarasow T; Janjic N
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4247-52. PubMed ID: 16189105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus.
    Maple PA; Hamilton-Miller JM; Brumfitt W
    J Antimicrob Chemother; 1992 Jun; 29(6):661-8. PubMed ID: 1506349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical development of mupirocin.
    Pappa KA
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):873-9. PubMed ID: 2112164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
    Jones RN; Thornsberry C
    Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
    Sader HS; Johnson DM; Jones RN
    Antimicrob Agents Chemother; 2004 Jan; 48(1):53-62. PubMed ID: 14693518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.
    Knaack D; Idelevich EA; Schleimer N; Molinaro S; Kriegeskorte A; Peters G; Becker K
    Diagn Microbiol Infect Dis; 2019 Apr; 93(4):362-368. PubMed ID: 30554844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of mupirocin E-test for determination of isolate susceptibility: comparison with standard agar dilution techniques.
    Simpson IN; Gisby J; Hemingway CP; Durodie J; Macpherson I
    J Clin Microbiol; 1995 Sep; 33(9):2254-9. PubMed ID: 7494011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
    Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mupirocin: a topical antibiotic with a unique structure and mechanism of action.
    Parenti MA; Hatfield SM; Leyden JJ
    Clin Pharm; 1987 Oct; 6(10):761-70. PubMed ID: 3146455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.